Article
Systematic Review of Epigenetic Therapies for Treatment of IDH-mutant Glioma.
World neurosurgery - 1 Jun 2022
Govindarajan Vaidya, Shah Ashish H, Di Long, Rivas Sarah, Suter Robert K, Eichberg Daniel G, Luther Evan, Lu Victor, Morell Alexis A, Ivan Michael E, Komotar Ricardo J, Ayad Nagi, De La Fuente Macarena
Abstract excerpt
BACKGROUND: Isocitrate dehydrogenase (IDH) mutations are present in 70% of World Health Organization grade II and III gliomas. IDH mutation induces accumulation of the oncometabolite 2-hydroxyglutarate. Therefore, therapies targeting reversal of epigenetic dysregulation in gliomas have been suggested. However, the utility of epigenetic treatments in gliomas remains unclear. Here, we present the first clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.